

# Hailin Tang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3931009/publications.pdf>

Version: 2024-02-01

129  
papers

6,295  
citations

46984

47  
h-index

82499

72  
g-index

137  
all docs

137  
docs citations

137  
times ranked

8782  
citing authors

#	ARTICLE	IF	CITATIONS
1	The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. <i>Molecular Cancer</i> , 2022, 21, 29.	7.9	47
2	Maackiain Modulates miR-374a/GADD45A Axis to Inhibit Triple-Negative Breast Cancer Initiation and Progression. <i>Frontiers in Pharmacology</i> , 2022, 13, 806869.	1.6	11
3	N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. <i>Nature Communications</i> , 2022, 13, 2672.	5.8	80
4	Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis. <i>EBioMedicine</i> , 2021, 63, 103137.	2.7	44
5	Isoliquiritigenin Suppresses EMT-Induced Metastasis in Triple-Negative Breast Cancer through miR-200c/C-JUN/I $\kappa$ 2-Catenin. <i>The American Journal of Chinese Medicine</i> , 2021, 49, 505-523.	1.5	26
6	Circular RNA circEPST11 accelerates cervical cancer progression via miR-375/409-3P/515-5p-SLC7A11 axis. <i>Aging</i> , 2021, 13, 4663-4673.	1.4	57
7	Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis. <i>Annals of Translational Medicine</i> , 2021, 9, 675-675.	0.7	52
8	Amplified electrochemical detection of circular RNA in breast cancer patients using ferrocene-capped gold nanoparticle/streptavidin conjugates. <i>Microchemical Journal</i> , 2021, 164, 106066.	2.3	13
9	Identification of a prognostic metabolic gene signature in diffuse large B-cell lymphoma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7066-7077.	1.6	11
10	New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9644.	1.8	33
11	Second invasive breast cancers in patients treated with breast-conserving therapy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2492-2498.	0.5	5
12	The biogenesis, function and clinical significance of circular RNAs in breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	8
13	Establishment of a prognostic ferroptosis-related gene profile in acute myeloid leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10950-10960.	1.6	13
14	Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13335.	1.8	31
15	Construction of an immune-related genes nomogram for the preoperative prediction of axillary lymph node metastasis in triple-negative breast cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2020, 48, 288-297.	1.9	30
16	Melatonin Regulates Breast Cancer Progression by the lnc010561/miR-30/FKBP3 Axis. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 765-774.	2.3	23
17	PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097421.	1.4	5
18	Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study. <i>Frontiers in Oncology</i> , 2020, 10, 580241.	1.3	31

#	ARTICLE	IF	CITATIONS
19	Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094092.	1.4	86
20	LncRNA SNORD3A specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMPS expression. <i>Cell Death and Disease</i> , 2020, 11, 329.	2.7	33
21	Protein phosphorylation networks in spargana of <i>Spirometra erinacei</i> revealed by phosphoproteomic analysis. <i>Parasites and Vectors</i> , 2020, 13, 248.	1.0	8
22	Breast-conserving therapy shows better prognosis in mucinous breast carcinoma compared with mastectomy: A SEER population-based study. <i>Cancer Medicine</i> , 2020, 9, 5381-5391.	1.3	8
23	Prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in breast: A meta-analysis of PSM studies. <i>Breast</i> , 2020, 51, 11-20.	0.9	16
24	Prognostic value of chronic hepatitis B virus infection in patients with breast cancer in a hepatitis B virus endemic area. <i>Annals of Translational Medicine</i> , 2020, 8, 180-180.	0.7	3
25	SOX2 Promotes Brain Metastasis of Breast Cancer by Upregulating the Expression of FSCN1 and HBEGF. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 118-129.	2.0	29
26	Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXC1 transcription in triple-negative breast cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 17.	6.9	74
27	Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer. <i>Cell Death and Differentiation</i> , 2020, 27, 2066-2080.	5.0	25
28	Isoliquiritigenin Derivative Regulates miR-374a/BAX Axis to Suppress Triple-Negative Breast Cancer Tumorigenesis and Development. <i>Frontiers in Pharmacology</i> , 2020, 11, 378.	1.6	23
29	Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple-negative breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 542-553.	2.3	36
30	Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study. <i>Cancer Control</i> , 2020, 27, 107327482097666.	0.7	11
31	Hepatitis B virus infection specially increases risk of liver metastasis in breast cancer patients: a propensity-matched analysis. <i>Translational Cancer Research</i> , 2020, 9, 1506-1517.	0.4	6
32	Circular RNAs as miRNA sponges in triple-negative breast cancer: a systematic review. <i>Minerva Biotecnologica</i> , 2020, 32, .	1.2	1
33	Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 179-190.	0.9	37
34	CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression. <i>Epigenomics</i> , 2019, 11, 1163-1176.	1.0	59
35	High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. <i>Journal of Cancer</i> , 2019, 10, 3239-3245.	1.2	49
36	Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 5994-6004.	1.6	52

#	ARTICLE	IF	CITATIONS
37	LCTL Is a Prognostic Biomarker and Correlates With Stromal and Immune Infiltration in Gliomas. <i>Frontiers in Oncology</i> , 2019, 9, 1083.	1.3	16
38	Nomogram to Predict Internal Mammary Lymph Nodes Metastasis in Patients With Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1193.	1.3	5
39	miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 8114-8127.	1.6	28
40	The Role of Circular RNA CDR1as/ciRS-7 in Regulating Tumor Microenvironment: A Pan-Cancer Analysis. <i>Biomolecules</i> , 2019, 9, 429.	1.8	87
41	circFBXW7 Inhibits Malignant Progression by Sponging miR-197-3p and Encoding a 185-aa Protein in Triple-Negative Breast Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 88-98.	2.3	167
42	Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?. <i>Cancer Communications</i> , 2019, 39, 1-12.	3.7	7
43	circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGF1 and FGF2 expression. <i>Carcinogenesis</i> , 2019, 40, 1469-1479.	1.3	53
44	circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. <i>Molecular Cancer</i> , 2019, 18, 23.	7.9	149
45	SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. <i>Carcinogenesis</i> , 2019, 40, 1278-1287.	1.3	29
46	Identification of a 4-mRNA metastasis-related prognostic signature for patients with breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 1439-1447.	1.6	25
47	CircAHNAK1 inhibits proliferation and metastasis of triple-negative breast cancer by modulating miR-421 and RASA1. <i>Aging</i> , 2019, 11, 12043-12056.	1.4	56
48	Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population-based study. <i>Cancer Medicine</i> , 2018, 7, 922-930.	1.3	57
49	Fabrication of multifunctional monometallic nanohybrids for reactive oxygen species-mediated cell apoptosis and enhanced fluorescence cell imaging. <i>Journal of Materials Chemistry B</i> , 2018, 6, 1187-1194.	2.9	14
50	Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2018, 97, 1275-1281.	2.5	58
51	Sensitive and simultaneous surface plasmon resonance detection of free and p53-bound MDM2 proteins from human sarcomas. <i>Analyst</i> , 2018, 143, 2029-2034.	1.7	4
52	Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer. <i>International Journal of Cancer</i> , 2018, 142, 1901-1910.	2.3	43
53	Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. <i>Cancer Management and Research</i> , 2018, Volume 10, 5329-5338.	0.9	124
54	AFAP1-AS1 Promotes Epithelial-Mesenchymal Transition and Tumorigenesis Through Wnt/ $\beta$ -Catenin Signaling Pathway in Triple-Negative Breast Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 1248.	1.6	54

#	ARTICLE	IF	CITATIONS
55	Incidence and Survival Outcomes of Breast Cancer with Synchronous Hepatic Metastases: A Population-Based Study. <i>Journal of Cancer</i> , 2018, 9, 4306-4313.	1.2	5
56	Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer. <i>Journal of Cancer</i> , 2018, 9, 3728-3735.	1.2	39
57	SOX2 Promotes Cell Proliferation and Metastasis in Triple Negative Breast Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 942.	1.6	59
58	Determination of the prognostic value of preoperative CA15â€³ and CEA in predicting the prognosis of young patients with breast cancer. <i>Oncology Letters</i> , 2018, 16, 4679-4688.	0.8	10
59	Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients. <i>Disease Markers</i> , 2018, 2018, 1-15.	0.6	61
60	Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a. <i>Oncogene</i> , 2018, 37, 6316-6326.	2.6	55
61	The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. <i>Journal of Cancer</i> , 2018, 9, 861-871.	1.2	47
62	LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. <i>Oncogene</i> , 2018, 37, 6166-6179.	2.6	101
63	Primary tumor resection in stage IV breast cancer: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1504-1512.	0.5	54
64	Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer. <i>Current Cancer Drug Targets</i> , 2018, 19, 74-80.	0.8	7
65	circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression. <i>Theranostics</i> , 2018, 8, 4003-4015.	4.6	199
66	Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials. <i>PLoS ONE</i> , 2018, 13, e0192464.	1.1	51
67	Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78- $\beta$ -catenin Signaling in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2018, 18, 390-399.	0.8	15
68	Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling. <i>Current Cancer Drug Targets</i> , 2018, 18, 592-599.	0.8	27
69	FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer. <i>Current Cancer Drug Targets</i> , 2018, 18, 382-389.	0.8	13
70	Abstract 520: circEPSTI1 as a prognostic marker and mediator of triple-negative breast cancer progression. <i>Cancer Research</i> , 2018, 78, 520-520.	0.4	1
71	Development and validation of a nomogram for predicting survival on the base of modified lymph node ratio in breast cancer patients. <i>Breast</i> , 2017, 33, 14-22.	0.9	31
72	The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. <i>Breast</i> , 2017, 32, 1-6.	0.9	74

#	ARTICLE	IF	CITATIONS
73	Multiplexed Electrochemical Detection of MiRNAs from Sera of Glioma Patients at Different Stages via the Novel Conjugates of Conducting Magnetic Microbeads and Diblock Oligonucleotide-Modified Gold Nanoparticles. <i>Analytical Chemistry</i> , 2017, 89, 10834-10840.	3.2	52
74	Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast. <i>Cancer Medicine</i> , 2017, 6, 2489-2496.	1.3	2
75	TMPyP Inhibits Amyloid- $\beta^2$ Aggregation and Alleviates Amyloid-Induced Cytotoxicity. <i>ACS Omega</i> , 2017, 2, 4188-4195.	1.6	12
76	AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 65.	3.5	58
77	miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 72.	2.2	43
78	Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: A systematic review and meta-analysis involving 186982 patients. <i>PLoS ONE</i> , 2017, 12, e0173862.	1.1	12
79	Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2017, 15, 210.	0.8	17
80	PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 129.	3.5	47
81	Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of $\beta$ -catenin stabilization in cancer stem cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 172.	3.5	67
82	circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 145.	3.5	277
83	Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer. <i>Journal of Cancer</i> , 2016, 7, 2309-2316.	1.2	34
84	Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 1747-1754.	1.2	23
85	Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0165133.	1.1	10
86	High expression of microRNA-183/182/96 cluster as a prognostic biomarker for breast cancer. <i>Scientific Reports</i> , 2016, 6, 24502.	1.6	47
87	The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2339-2345.	1.2	28
88	High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. <i>Breast</i> , 2016, 30, 39-46.	0.9	102
89	Amplified voltammetric detection of miRNA from serum samples of glioma patients via combination of conducting magnetic microbeads and ferrocene-capped gold nanoparticle/streptavidin conjugates. <i>Biosensors and Bioelectronics</i> , 2016, 86, 502-507.	5.3	41
90	The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer. <i>Scientific Reports</i> , 2016, 6, 21735.	1.6	109

#	ARTICLE	IF	CITATIONS
91	Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients. PLoS ONE, 2016, 11, e0161902.	1.1	23
92	Diagnostic and prognostic value of serum MACC1 in breast cancer patients. Oncotarget, 2016, 7, 84408-84415.	0.8	21
93	mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK. Oncotarget, 2016, 7, 35188-35198.	0.8	55
94	LGR5 Promotes Breast Cancer Progression and Maintains Stem-Like Cells Through Activation of Wnt/ $\beta$ -Catenin Signaling. Stem Cells, 2015, 33, 2913-2924.	1.4	135
95	microRNA-22 acts as a metastasis suppressor by targeting metadherin in gastric cancer. Molecular Medicine Reports, 2015, 11, 454-460.	1.1	30
96	Caveolin-1, a stress-related oncotarget, in drug resistance. Oncotarget, 2015, 6, 37135-37150.	0.8	57
97	MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells. Oncotarget, 2015, 6, 7930-7943.	0.8	34
98	Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: A retrospective study. Cancer Biomarkers, 2015, 15, 115-123.	0.8	4
99	miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Letters, 2015, 357, 384-392.	3.2	85
100	ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH. Molecular Cancer, 2015, 14, 84.	7.9	35
101	Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Letters, 2015, 356, 374-381.	3.2	10
102	miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. Cancer Letters, 2015, 356, 410-417.	3.2	81
103	Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation. Oncotarget, 2015, 6, 9854-9876.	0.8	67
104	MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget, 2015, 6, 20070-20083.	0.8	60
105	miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget, 2015, 6, 34968-34978.	0.8	72
106	Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma. Journal of Cancer Research and Therapeutics, 2015, 11, 630-634.	0.3	47
107	BikDDA, a Mutant of Bik with Longer Half-Life Expression Protein, Can Be a Novel Therapeutic Gene for Triple-Negative Breast Cancer. PLoS ONE, 2014, 9, e92172.	1.1	5
108	Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 1813-1825.	1.9	13

#	ARTICLE	IF	CITATIONS
109	Efficient systemic DNA delivery to the tumor by self-assembled nanoparticle. <i>Journal of Nanoparticle Research</i> , 2014, 16, 1.	0.8	2
110	miR-185 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer. <i>Molecular and Cellular Biochemistry</i> , 2014, 386, 223-231.	1.4	63
111	miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. <i>Journal of Translational Medicine</i> , 2014, 12, 17.	1.8	64
112	microRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. <i>Molecular and Cellular Biochemistry</i> , 2014, 392, 153-159.	1.4	83
113	miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3185-3197.	1.9	93
114	Disturbing miR-182 and -381 Inhibits BRD7 Transcription and Glioma Growth by Directly Targeting LRRC4. <i>PLoS ONE</i> , 2014, 9, e84146.	1.1	49
115	Diallyl Disulfide Suppresses SRC/Ras/ERK Signaling-Mediated Proliferation and Metastasis in Human Breast Cancer by Up-Regulating miR-34a. <i>PLoS ONE</i> , 2014, 9, e112720.	1.1	67
116	Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. <i>Cancer Letters</i> , 2013, 340, 72-81.	3.2	109
117	miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma. <i>Tumor Biology</i> , 2013, 34, 1793-1800.	0.8	66
118	Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. <i>Molecular and Cellular Biochemistry</i> , 2013, 382, 103-111.	1.4	97
119	miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression. <i>Clinical Cancer Research</i> , 2013, 19, 5602-5612.	3.2	152
120	MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1. <i>PLoS ONE</i> , 2013, 8, e65138.	1.1	100
121	The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas. <i>Current Cancer Drug Targets</i> , 2013, 13, 221-231.	0.8	77
122	LRRC4 Inhibits Glioma Cell Growth and Invasion Through a miR-185- Dependent Pathway. <i>Current Cancer Drug Targets</i> , 2012, 12, 1032-1042.	0.8	57
123	Direct Quantification of MicroRNA at Low Picomolar Level in Sera of Glioma Patients Using a Competitive Hybridization Followed by Amplified Voltammetric Detection. <i>Analytical Chemistry</i> , 2012, 84, 6400-6406.	3.2	101
124	F10 gene hypomethylation, a putative biomarker for glioma prognosis. <i>Journal of Neuro-Oncology</i> , 2012, 107, 479-485.	1.4	14
125	Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. <i>Brain Research</i> , 2011, 1390, 21-32.	1.1	94
126	POTEH hypomethylation, a new epigenetic biomarker for glioma prognosis. <i>Brain Research</i> , 2011, 1391, 125-131.	1.1	19



#	ARTICLE	IF	CITATIONS
127	MiR-185 Targets the DNA Methyltransferases 1 and Regulates Global DNA Methylation in human glioma. Molecular Cancer, 2011, 10, 124.	7.9	106
128	miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. Journal of Cell Science, 2011, 124, 2997-3005.	1.2	147
129	Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer. Frontiers in Oncology, 0, 12, .	1.3	9